Evidence map›Paper›PMID 35896852›Full record

ArticleBreast cancer research and treatment2022

Intermedin (adrenomedullin 2) promotes breast cancer metastasis via Src/c-Myc-mediated ribosome production and protein translation.

Lingmiao Kong, Ying Xiong, Denian Wang, Luping Huang, Min Li, Zhongxue Feng, Yue Zhou, Haili Zhang, Fei Liu, Fei Xiao and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Lingmiao Kong *Department of Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, No. 2222, Frontier Medical Center, Xin Chuan Road, Zhong He Street, Chengdu, 610212, Sichuan, People's Republic of China.
Ying Xiong *Department of Periodical Press, West China Hospital, Sichuan University, Chengdu, China.
Denian WangDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Luping HuangDepartment of Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, No. 2222, Frontier Medical Center, Xin Chuan Road, Zhong He Street, Chengdu, 610212, Sichuan, People's Republic of China.
Min LiDepartment of Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, No. 2222, Frontier Medical Center, Xin Chuan Road, Zhong He Street, Chengdu, 610212, Sichuan, People's Republic of China.
Zhongxue FengDepartment of Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, No. 2222, Frontier Medical Center, Xin Chuan Road, Zhong He Street, Chengdu, 610212, Sichuan, People's Republic of China.
Yue ZhouDepartment of Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, No. 2222, Frontier Medical Center, Xin Chuan Road, Zhong He Street, Chengdu, 610212, Sichuan, People's Republic of China.
Haili ZhangDepartment of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
Fei LiuDepartment of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
Fei XiaoDepartment of Intensive Care Unit of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Yong'gang WeiDepartment of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China. yourwyg@163.com.
Wei ZhangDepartment of Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, No. 2222, Frontier Medical Center, Xin Chuan Road, Zhong He Street, Chengdu, 610212, Sichuan, People's Republic of China. zhangwei197610@163.com.ORCID http://orcid.org/0000-0001-7588-7249
Sichuan University · CN

Funding

Natural Science Foundation of China 81971811Natural Science Foundation of China 81972729Sichuan Province Science and Technology Support Program 2019YFS0370Sichuan Province Science and Technology Support Program 2019YFS0372Sichuan Province Science and Technology Support Program 2020YFS0203
6 · The paper itself

Abstract

purposeBreast cancer is the most frequently diagnosed cancer and is the leading cause of cancer-associated mortality in women worldwide. Intermedin (IMD, also known as Adrenomedullin 2, ADM2) is an endogenous peptide that belongs to the calcitonin gene-related peptide family and has been reported to play important roles in several types of cancers, including breast cancer. In this study, we sought to investigate how IMD affects the behavior of breast cancer cells, the underlying mechanism of these effects, and whether blockade of IMD has a therapeutic effect against breast cancer.

methodsTranscriptome sequencing (RNA-Seq), cell biological experiments, Western blotting, immunoprecipitation, and animal tumor models were used.

resultsIMD expression was significantly increased in breast cancer samples, and the IMD level was positively correlated with lymph node metastasis and Ki67 expression. Cell biological experiments showed that IMD promoted the anchorage-independent growth, migration, and invasive ability of breast cancer cells. Inhibiting IMD activity with an anti-IMD monoclonal antibody blocked these tumor-promoting effects. In addition, blockade of IMD reduced in situ tumor growth and significantly decreased lung metastasis of 4T1 breast cancer in vivo. IMD induced Src kinase phosphorylation, which triggered the transcription of c-Myc, a major oncoprotein controlling the expression of genes that encode ribosomal components. Our data suggest that IMD is involved in breast cancer cell invasion and metastasis, potentially through increasing ribosome biogenesis and protein translation via the Src/c-Myc signaling pathway.

conclusionThese results suggest that IMD may be a novel target for the treatment of breast cancer.

Indexed as

Breast NeoplasmsNeuropeptidesRibosomesSignal TransductionAdrenomedullinAnimalsFemaleHumansPeptide HormonesProtein BiosynthesisProto-Oncogene Proteins c-mycADM2 protein, humanAdrenomedullinNeuropeptidesPeptide HormonesProto-Oncogene Proteins c-mycAdrenomedullin 2 (ADM2)Breast cancerc-MycIntermedin (IMD)MetastasisRibosomal biogenesisSrc

Identifiers

PMID35896852
OpenAlexW4288066549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.